Effect of Expanded Hemodialysis with Theranova Dialyzer on Preservation of Residual Kidney Function in Incident Hemodialysis Patients: THREAD Randomized Controlled Trial

Background: Expanded hemodialysis (HDx) using a medium cut-off dialyzer can improve the clearance of middle-molecular uremic toxins compared to conventional hemodialysis (HD). However, its effect on residual kidney function (RKF) remains unclear. This study evaluated the effect of HDx on preserving RKF in incident HD patients. Methods: Patients who initiated HD were randomized to receive dialysis with either an HDx with Theranova 400 or a high-flux (HF) dialyzer with a similar surface area over 12 months. The primary outcome was a change of glomerular filtration rate (GFR) over 12 months, as determined by the average of urea and creatinine clearance. The secondary outcome was a change in 24-hour urine volume, middle molecules, and kidney injury markers. Results: A total of 80 HD patients (mean age: 62.7±11.9 years; male: 52 [65.0%]) underwent randomization. During 12 months, the Theranova group demonstrated a significantly smaller decrease in GFR than the HF group (−1.20 [IQR, −2.29, −0.22] mL/min/1.73m2 vs. −2.24 [IQR, −3.62, −0.46] mL/min/1.73m2, P=0.019) (Fig 1). No significant difference in 24-hour urine volume was observed at 12-month, whereas Theranova maintained greater 24-hour urine volume until 9-month compared to the HF dialyzer. After 12 months, the Theranova group showed a significantly lower increase in β2-microglobulin. The increase in kidney injury markers such as IGFBP-7 and KIM-1 was significantly reduced in the Theranova group compared to the HF group. The reduction ratio for κ/λ free light chains, TNF-α. and GDF-15 was higher in the Theranova group than the HF group. There were no differences in hospitalization rate or mortality between the two groups. Conclusion: HDx using the Theranova dialyzer has preserved the decline in RKF compared to the HF dialyzer of similar size in newly initiated HD patients. Funding: Commercial Support - Baxter

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2024-10-01
DOI
https://doi.org/10.1681/asn.2024fbq9wr6t
Primary Topic
Dialysis and Renal Disease Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of Expanded Hemodialysis with Theranova Dialyzer on Preservation of Residual Kidney Function in Incident Hemodialysis Patients: THREAD Randomized Controlled Trial

Hyung Duk Kim, Chan‐Duck Kim, Hee‐Yeon Jung, Jeong‐Hoon Lim et al.
Journal of the American Society of Nephrology
Dialysis and Renal Disease Management
article

Effect of Expanded Hemodialysis with Theranova Dialyzer on Preservation of Residual Kidney Function in Incident Hemodialysis Patients: THREAD Randomized Controlled Trial

Hyung Duk Kim, Chan‐Duck Kim, Hee‐Yeon Jung, Jeong‐Hoon Lim, Jang‐Hee Cho, You Hyun Jeon, Y. Oh, Mingyu Kim, Sun-Hee Park
article en

Abstract

Background: Expanded hemodialysis (HDx) using a medium cut-off dialyzer can improve the clearance of middle-molecular uremic toxins compared to conventional hemodialysis (HD). However, its effect on residual kidney function (RKF) remains unclear. This study evaluated the effect of HDx on preserving RKF in incident HD patients. Methods: Patients who initiated HD were randomized to receive dialysis with either an HDx with Theranova 400 or a high-flux (HF) dialyzer with a similar surface area over 12 months. The primary outcome was a change of glomerular filtration rate (GFR) over 12 months, as determined by the average of urea and creatinine clearance. The secondary outcome was a change in 24-hour urine volume, middle molecules, and kidney injury markers. Results: A total of 80 HD patients (mean age: 62.7±11.9 years; male: 52 [65.0%]) underwent randomization. During 12 months, the Theranova group demonstrated a significantly smaller decrease in GFR than the HF group (−1.20 [IQR, −2.29, −0.22] mL/min/1.73m2 vs. −2.24 [IQR, −3.62, −0.46] mL/min/1.73m2, P=0.019) (Fig 1). No significant difference in 24-hour urine volume was observed at 12-month, whereas Theranova maintained greater 24-hour urine volume until 9-month compared to the HF dialyzer. After 12 months, the Theranova group showed a significantly lower increase in β2-microglobulin. The increase in kidney injury markers such as IGFBP-7 and KIM-1 was significantly reduced in the Theranova group compared to the HF group. The reduction ratio for κ/λ free light chains, TNF-α. and GDF-15 was higher in the Theranova group than the HF group. There were no differences in hospitalization rate or mortality between the two groups. Conclusion: HDx using the Theranova dialyzer has preserved the decline in RKF compared to the HF dialyzer of similar size in newly initiated HD patients. Funding: Commercial Support - Baxter

Journal of the American Society of NephrologyVol. 35(10S)
Kyungpook National University (KR)
Zero hunger
Openalex Percentile: Top 74%
Dialysis and Renal Disease Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.